BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-01-23 08:30 |
Extraordinary General Meeting in BioInvent is cancelled
|
English | 44.0 KB | ||
| 2017-01-23 08:30 |
Inställd extra bolagsstämma i Bioinvent
|
Swedish | 42.0 KB | ||
| 2017-01-10 17:40 |
BioInvents samarbetspartner ThromboGenics startar fas II-studie med läkemedelsk…
|
Swedish | 61.9 KB | ||
| 2017-01-10 17:40 |
BioInvent’s collaboration partner ThromboGenics initiates Phase II study with t…
|
English | 45.6 KB | ||
| 2016-12-30 10:22 | English | 34.4 KB | |||
| 2016-12-30 08:30 |
Kallelse till extra bolagsstämma i BioInvent International AB
|
Swedish | 46.2 KB | ||
| 2016-12-30 08:30 |
Notice of Extraordinary General Meeting in BioInvent International AB
|
English | 49.7 KB | ||
| 2016-12-21 08:00 |
BioInvent announces Cancer Immunotherapy Research Collaboration and License Agr…
|
English | 224.9 KB | ||
| 2016-12-21 08:00 |
BioInvent ingår forskningssamarbete och licensavtal inom cancerimmunterapi med …
|
Swedish | 238.7 KB | ||
| 2016-12-09 16:45 |
BioInvent avslutar pågående fas II-studie med BI-505
|
Swedish | 302.5 KB | ||
| 2016-12-09 16:45 |
BioInvent terminates current BI-505 Phase II study
|
English | 210.8 KB | ||
| 2016-11-08 12:00 |
BioInvent rapporterar ”clinical hold” för fas II-studie med BI-505
|
Swedish | 304.2 KB | ||
| 2016-11-08 12:00 |
BioInvent reports clinical hold on BI-505 phase II study
|
English | 210.3 KB | ||
| 2016-11-07 10:17 | English | 34.0 KB | |||
| 2016-10-25 08:40 | Swedish | 553.7 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
